Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 11/07/23 07:00:59 on US and Canada Markets.
Financial Overview - Third Quarter Revenues of $139 Million, Down 4% From a Year Ago Adjusted Operating Income Margin of 8.5%, GAAP Operating Loss Margin of (19.2)% Adjusted EPS of $0.12; GAAP Diluted EPS of $(0.27) Financial Overview - Nine Months Revenues of $4...
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and liv...
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current o...
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of ...
3Q 2023 ZYNLONTA ® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses decreased 23% 2 year-over-year due to portfolio prioritiz...
AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”) , a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the third...
Datadog Announces Third Quarter 2023 Financial Results PR Newswire Third quarter revenue grew 25% year-over-year to $548 million Strong growth of larger customers, with about 3,130 $100k+ ARR customers, up from about 2,600 a year ago NEW YORK , No...
― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024 ― ― U.S. Food and Drug Administration (FDA) lifted clinical hold for pociredir (formerly FTX-6...
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR Canada NewsWire Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm , MD, and Sean Pokorney , MD ...
Misconceptions about costs discourage sustainable investing Canada NewsWire New survey from Co-operators finds that Canadians want to act sustainably but are concerned about the price of going "green" TORONTO , Nov. 7, 2023 /CNW/ - The perceived cost of ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
26.98%Change Percent:
Spectralcast Inc Company Name:
SPEC Stock Symbol:
NASDAQ Market:
www.perceptionii.com Website: